Attached files
| file | filename |
|---|---|
| EX-10.8 - EX-10.8 - Radius Health, Inc. | a16-6577_1ex10d8.htm |
| EX-10.9 - EX-10.9 - Radius Health, Inc. | a16-6577_1ex10d9.htm |
| EX-31.1 - EX-31.1 - Radius Health, Inc. | a16-6577_1ex31d1.htm |
| EX-10.1 - EX-10.1 - Radius Health, Inc. | a16-6577_1ex10d1.htm |
| EX-10.4 - EX-10.4 - Radius Health, Inc. | a16-6577_1ex10d4.htm |
| EX-10.10 - EX-10.10 - Radius Health, Inc. | a16-6577_1ex10d10.htm |
| EX-10.3 - EX-10.3 - Radius Health, Inc. | a16-6577_1ex10d3.htm |
| EX-10.7 - EX-10.7 - Radius Health, Inc. | a16-6577_1ex10d7.htm |
| EX-10.12 - EX-10.12 - Radius Health, Inc. | a16-6577_1ex10d12.htm |
| EX-31.2 - EX-31.2 - Radius Health, Inc. | a16-6577_1ex31d2.htm |
| EX-10.13 - EX-10.13 - Radius Health, Inc. | a16-6577_1ex10d13.htm |
| 10-Q - 10-Q - Radius Health, Inc. | a16-6577_110q.htm |
| EX-10.5 - EX-10.5 - Radius Health, Inc. | a16-6577_1ex10d5.htm |
| EX-10.6 - EX-10.6 - Radius Health, Inc. | a16-6577_1ex10d6.htm |
| EX-10.11 - EX-10.11 - Radius Health, Inc. | a16-6577_1ex10d11.htm |
| EX-32.1 - EX-32.1 - Radius Health, Inc. | a16-6577_1ex32d1.htm |
Exhibit 10.2
Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2
Statement of Work
To the Agreement between RADIUS HEALTH, INC. (“RADIUS”) and LONZA Sales AG dated 16 of October 2007
Supplemental analytical services
|
Number |
|
RDS-001-SC004 |
|
|
|
Product Code/Name |
|
RDS-001 Abaloparatide |
|
|
|
Description of the proposed change: |
|
Supplemental services requested by Radius: 1) Manufacturing of an RS solution and supply of 60 vials to Vetter 2) Additional LC-MS analysis (M-076-RDS-001) and reissue a new CoA of batch 2AN1. | ||
|
|
|
| ||
|
Price Agreed |
|
1. [*]€ 2. [*]€
Total: [*]€ |
|
|
|
Radius |
|
Name: Naveen Palwai |
|
Date : 11 Mar 2016 |
|
Radius |
|
Name: Signature: /s/ David Hanley |
|
Date : 11 Mar 2016 |
|
Lonza Sales AG |
|
Name : Paul Tastenhoye Signature : /s/ Paul Tastenhoye |
|
Date: 11/03/2016 |
|
Lonza Sales AG |
|
Name : Frederique Mutterer Signature : /s/ Frederique Mutterer |
|
Date : 11/03/16 |
Additional notes: /
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2
Detailed description of the proposed change
Activity 1: Manufacturing of an RS solution and supply of 60 vials to Vetter. Radius to communicate which reference standard is to be used for this liquid reference solution.
Activity 2: Additional LC-MS analysis (M-076-RDS-001) and reissue a new CoA of batch 2AN1.
Timescale
Activity 1: By mid-May
Activity 2: By March 25th (prior to NDA filing)
Price and Terms of Payment
1. Price
· Activity 1: [*]€
· Activity 2: [*]€
· Total price: [*]€
2. Payment
100% upon completion
oooOOOooo
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.